Related Experiment Video

Updated: Jun 17, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Toll-like receptors: cost or benefit for cancer?

T Matijevic1, J Pavelic

  • 1Rudjer Boskovic Institute Division of Molecular Medicine, Bijenicka 54, 10000 Zagreb, Croatia.

Current Pharmaceutical Design
|December 25, 2009
PubMed

Insights

Toll-like receptors (TLRs) are key in immune defense and show a dual role in cancer. They can promote or inhibit tumor growth, making them promising therapeutic targets for cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Toll-like receptors (TLRs) are crucial for innate immunity, primarily defending against microbial infections.
  • TLRs are expressed on immune cells like macrophages and dendritic cells (DCs), initiating immune responses upon ligand binding.
  • The role of TLRs on epithelial and tumor cells is complex and requires further investigation.

Purpose of the Study:

  • To explore the dual role of Toll-like receptors (TLRs) in cancer.
  • To assess the potential of TLRs as therapeutic targets and immunostimulatory agents in cancer treatment.
  • To highlight the necessity of comprehensive studies on TLRs in neoplastic cells.

Main Methods:

  • Review of existing literature on Toll-like receptor (TLR) function in microbial defense and cancer.
  • Analysis of studies investigating TLR expression and function in various tumor types.
  • Examination of preclinical and clinical data on TLR ligands as immunostimulatory agents in cancer therapy.

Main Results:

  • TLRs exhibit a dual role in cancer: promoting tumor proliferation/survival in some types, and inducing apoptosis (e.g., TLR2, -3, -9) in others.
  • TLR ligands show potential as immunostimulatory molecules for cancer treatment, with varied outcomes depending on the adjuvant used.
  • Neoplastic processes can manipulate signaling pathways, influencing the overall effect of TLRs in cancer.

Conclusions:

  • Toll-like receptors (TLRs) represent promising candidates for novel cancer therapeutics, either as direct targets or for immunostimulation.
  • Careful selection of adjuvants is critical for effective cancer patient treatment involving TLRs, due to potentially beneficial or deleterious immune responses.
  • Further comprehensive research is essential to fully elucidate the significance of TLRs in neoplastic cells and optimize their therapeutic application.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...